| Title |
An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
|
|---|---|
| Published in |
OncoTargets and therapy, June 2015
|
| DOI | 10.2147/ott.s78925 |
| Pubmed ID | |
| Authors |
Ying Zhang, Huaping Tang, Jun Li, Meng Li |
| Abstract |
Lung cancer has the highest mortality rate of all cancers worldwide. A total of 70%-75% of all lung cancers are non-small cell lung cancer (NSCLC) with two-thirds presenting with locally advanced or metastatic disease at diagnosis. Brain metastasis is one of the most common problems in the management of NSCLC, worsening the prognosis and quality of life of NSCLC patients. The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been tested in patients with NSCLC and brain metastasis. Icotinib is a new type of oral EGFR-TKI. In this report, we describe a patient with lung adenocarcinoma cancer with brain metastases who received icotinib treatment and kept satisfactory health-related quality of life for 1 year. |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 5% |
| Unknown | 18 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 26% |
| Researcher | 3 | 16% |
| Other | 2 | 11% |
| Student > Bachelor | 2 | 11% |
| Professor | 1 | 5% |
| Other | 3 | 16% |
| Unknown | 3 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Psychology | 3 | 16% |
| Medicine and Dentistry | 3 | 16% |
| Biochemistry, Genetics and Molecular Biology | 2 | 11% |
| Agricultural and Biological Sciences | 2 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Other | 3 | 16% |
| Unknown | 5 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 June 2015.
All research outputs
#22,756,649
of 25,371,288 outputs
Outputs from OncoTargets and therapy
#2,078
of 3,016 outputs
Outputs of similar age
#240,020
of 281,399 outputs
Outputs of similar age from OncoTargets and therapy
#49
of 71 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,399 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.